Symptom Management at the End of Life

Pain Management

  • In a survey of 310 patients with serious, life-limiting illnesses, freedom from pain was ranked number one in importance (Steinhauser 2000).
  • The SUPPORT study found that fully half of bereaved family members thought their loved ones were in moderate to severe pain 50% of the time in the last 72 hours of life (SUPPORT 1995).
  • With good palliative care, most deaths can indeed be peaceful and relatively free of discomfort, although symptom management remains challenging (Lichter 1990Ellershaw 2001).
  • Of major physical symptoms, pain and dyspnea are both prevalent and distressing, if not skillfully addressed (SUPPORT, 1995Hall 2002Teno 2004).
  • Among actively dying cancer patients, prevalence rates for pain range from 51% to 100% and for dyspnea, from 22% to 46% (Lichter 1990Ventafridda 1990Coyle 1990Fainsinger 1991).

 

Dyspnea

 

  • Studies of non-cancer patients are limited, but suggest that such patients may have more difficulty with dyspnea than do cancer patients. In a chart audit of 238 deceased nursing home patients of which only 14% had cancer, 42% were noted to have pain and 62% experienced dyspnea in the last 48 hours (Hall2002).
  • Many patients and families fear worsening of symptoms as death approaches and may need reassurance that such is not necessarily the case. Good medical management can usually provide reasonable palliation.
  • In a study of 200 cancer patients followed by a home and inpatient hospice program Lichter judged 91.5% of deaths to be peaceful (Lichter and Hunt, 1990).
  • Ellershaw found that 85% of 168 cancer patients had good symptom. In separate studies, both Ellershaw and Conill found that prevalence of pain in treated cancer patients tended to decrease over the last few days and hours of life (Ellershaw 2001Conill 1997).
  • Conill also found that other symptoms increased in frequency over the final 2 weeks of life – asthenia (76.7% increasing to 81.8%), anorexia (68.2% to 80.1%), and dry mouth (61.4% to 69.9%).
  • See module on dyspnea for other details.

 

Other symptoms

 

  • The symptom showing the greatest increase in prevalence was mental confusion (30.1% to 68.2%).
  • Studies on confusional states in the terminal phase have revealed varying prevalence rates. Overall, it appears that as many as 85% of people experience some altered mental status or delirium (Fainsinger, 1998Breitbart 2000).
  • In one study, delirium was reversible in only 49% of cases, despite best efforts (Lawlor 2000).
  • Not all such altered states are distressing (Hallenbeck, 2003).
  • However, Ellershaw found that 13.4% of patients were agitated at 48 hours prior to death. With therapy, agitation decreased (Ellershaw 2001).
  • Many dying patients display signs of retained respiratory secretions, sometimes called the “death rattle” (Ellershaw 2001). Although this is often disturbing to family members, it is unclear whether patients themselves find it distressing.

 

Treatment

 

  • Comprehensive reviews of treatment options for symptoms in the last 48 hours are readily available (Storey, 1998O’Neill 1997).
  • Standardized clinical pathways for care of the actively dying are just beginning to emerge (Ellershaw2001Ellershaw 2003). Opioids are commonly administered for pain and dyspnea.

 

As in this case, with non-verbal patients, it is not always clear if observed changes reflect suffering. Mr. Stanton’s increased respiratory rate may have been a sign of increasing dyspnea, pain, or underlying agitation. Alternatively, it might simply have reflected a compensatory respiratory alkalosis in response to a metabolic acidosis with no associated suffering.

Generally, opioids previously instituted should be continued in the last 48 hours. Commonly, the dose is increased by 25-50% to treat the possibility of increased pain or dyspnea.

In non-hospital settings, identification of an alternative route of drug administration for patients who are no longer able to use the oral route may be challenging. In such circumstances, subcutaneous infusions, transdermal preparations, nebulizations, and concentrated oral solutions may be useful (Cherny 1995;Herndon 2001Chandler, 1999).

Relief of dyspnea best correlates with steady-state blood levels of opioids, as does pain relief. Suppression of respiratory drive is strongly correlated with rapid rises in opioid blood levels, not steady-state levels. Dyspnea relief is not a function of respiratory drive suppression (Bruera 1990Mazzocato 1999Dyspnea, 1999,Jennings 2002).

There is no evidence that opioids, when reasonably and properly administered at the end-of-life, hasten death (Campbell, 2004). While it is reasonable to treat pain or dyspnea presumptively, the goal of such therapy should not be simply to reduce the respiratory rate per se; it is just one of a number of possible markers of distress. Oxygen administration may also relieve dyspnea via mechanisms other than by raising oxygen saturation (Watanabe, 2000).

Agitated Delirium

Traditionally, care for agitated delirium emphasizes attempting to clear the sensorium. However, in the last 48 hours this is not possible for the majority of patients (Lawlor 2000). In all cases, the clinician should search for and treat correctable causes of agitation, such as medication side-effects, pain, bladder distention, or other physical discomforts.

In non-verbal patients, it is not always possible to determine if physical discomfort is causing agitation. Often palliative therapies are attempted in an iterative fashion, to determine if agitation is reduced or not. If no such conditions are identified, sedating agents such as benzodiazepines, neuroleptics such as chlorpromazine, or even barbiturates may be used, following consultation and informed consent from the patient, family member, or proxy. In most cases, small doses of these agents suffice to relieve agitation. Seldom is there a need for administration of high doses of sedating agents, so-called terminal or palliative sedation, for symptoms (Morita2002Rousseau, 2003). There is no evidence that the use of sedating agents at the end of life, when properly administered, hastens death (Morita 2001). Because families are understandably distressed at witnessing delirium in the dying person, they may benefit from emotional support from clinicians (Morita 2004Breitbart2002).

Respiratory Secretions

Retained respiratory secretions can be treated with anticholinergic agents such as atropine, scopolamine or glycopyrrolate, and by turning the patient to the side (Back 2001Wildiers 2002). In this case, atropine eye drops were given sublingually, as is common practice in many hospices and palliative care units. Although there is anecdotal concern that atropine may be a less desirable agent to use because it may cause agitation, there are no good clinical trials comparing atropine with other drugs. Deep suctioning is uncomfortable and should be avoided.

 

Translate »